Nurix Therapeutics, Inc.
BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF
Last updated:
Abstract:
The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteosome pathway, and method for treating diseases modulated by HPK1.
Status:
Application
Type:
Utility
Filling date:
5 May 2021
Issue date:
18 Nov 2021